Novo Nordisk’s Wegovy sales weaken as Eli Lilly’s Zepbound exerts pressure
Shares in Novo Nordisk slid as supply bottlenecks and a more crowded weight loss treatment space depress Wegovy sales.
08 August 2024
08 August 2024
Shares in Novo Nordisk slid as supply bottlenecks and a more crowded weight loss treatment space depress Wegovy sales.
Precigen also plans to raise $30m to focus on advancing its RRP candidate PRGN-2012.
The formulation of CREXONT combines immediate-release granules and extended-release pellets to provide sustained efficacy.
The company plans to use the Series B proceeds to finance Phase I and pivotal trials for IDRX-42, licensed from Merck KGaA.
As WHO reports a high HBV burden, Aligos Therapeutics’ CEO highlighted the potential for pharma to address unmet needs.
The approval is based on interim results from the Phase III APPLAUSE-IgAN study.
The EC's decision was informed by comprehensive data from a Phase III trial and continuation study of ADZYNMA.
The approval allows Jemperli to be used in combination with chemotherapy for immuno-oncology treatment in the frontline setting.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.